insights_auto
Miks on NTLA tõusnud? 5,34%?
Uurige põhjalikumaltchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
12,03Â $
arrow_upward
+5,34%(+0,61) 1 p
11,97Â $
arrow_downward
−0,50% (−0,060)bedtimePärast tööaega
Suletud: 29. sept, 16:00:00 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse NTLA põhistatistika genereerimine…
Ava
11,49Â $
Kõrge
12,05Â $
Madal
11,42Â $
Turu kapit.
1,69Â mld
Keskm. maht
3,81Â mln
Maht
5,02Â mln
52 näd kõrgeim
28,24Â $
52 näd madalaim
7,95Â $
Aktsiatulu
−3,36 $
Beeta
1,82
Käibivad aktsiad
140,13Â mln
Töötajate arv
377
Ava
11,49Â $
Kõrge
12,05Â $
Madal
11,42Â $
Turu kapit.
1,69Â mld
Keskm. maht
3,81Â mln
Maht
5,02Â mln
52 näd kõrgeim
28,24Â $
52 näd madalaim
7,95Â $
Aktsiatulu
−3,36 $
Beeta
1,82
Käibivad aktsiad
140,13Â mln
Töötajate arv
377
Uudised
Veebiallikatest ja uudistepartneritelt
Yahoo Finance
·
10 tunni eest
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Yahoo Finance
·
2 päeva eest
Could This Cathie Wood Stock Soar in 2027?
Seeking Alpha
·
2 päeva eest
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA)
Profiil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Teave üksuse Intellia Therapeutics Inc kohta
TegevjuhtJohn Leonard
Töötajad377
Asutatud2014
PeakontoridCambridge, Massachusetts, Ameerika Ãœhendriigid
Sektor-
Veebisaitintelliatx.com